Study on the mechanism of Folium Epimedii and Ligustri Lucidi Fructus compatibility against airway inflammation in asthmatic rats based on cAMP/PKA/CREB pathway

May 1, 2026Lishizhen medicine and materia medica research

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to explore the therapeutic effects of Folium Epimedii and Ligustri Lucidi on airway inflammation in asthma using the cAMP/PKA/CREB pathway.
Used SPF male SD rats, randomly divided into groups: normal, asthma model, Folium Epimedii, Ligustri Lucidi, and combination group (Folium Epimedii + Ligustri Lucidi).
Established asthma model via ovalbumin sensitization and treated with oral administration for 2 weeks. Tested plasma and lung tissue for relevant biomarkers using ELISA.
Analyzed protein and mRNA expression through Western blot and qRT-PCR to evaluate effects on the cAMP/PKA/CREB signaling pathway.
Asthmatic rats showed significantly increased IgE, IL-6, and MDA levels compared to the normal group (P<0.01 or P<0.05) and decreased SOD activity (P<0.01).
Treatment groups reduced IgE, IL-6, and MDA levels and increased SOD activity significantly (P<0.01 or P<0.05), with the combination group showing the most improvement.
Combination treatment notably upregulated cAMP/PKA/CREB pathway proteins and mRNA expression (P<0.01).

Investigates Folium Epimedii and Ligustri Lucidi's effects on airway inflammation in asthmatic rats, suggesting significant therapeutic potential.

No takes yet. Share an insight, caveat, or question.

MA et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share